Lunn, R M <br/><br/>
Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).  [electronic resource] 

 -  Carcinogenesis  Sep 1999 
 - 1727-31 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>0143-3334 
<br/><br/><label>Standard No.: </label>10.1093/carcin/20.9.1727  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>3-Oxo-5-alpha-Steroid 4-Dehydrogenase--genetics<br/>Adenocarcinoma--enzymology<br/>Asian People--genetics<br/>Black People--genetics<br/>Case-Control Studies<br/>Dihydrotestosterone--metabolism<br/>Gene Frequency<br/>Genetic Predisposition to Disease<br/>Genotype<br/>Humans<br/>Isoenzymes--genetics<br/>Male<br/>Neoplasms, Hormone-Dependent--enzymology<br/>North Carolina--epidemiology<br/>Odds Ratio<br/>Polymorphism, Genetic<br/>Prostatic Neoplasms--enzymology<br/>Risk<br/>Steroid 17-alpha-Hydroxylase--genetics<br/>Taiwan<br/>Testosterone--metabolism<br/>White People--genetics<br/>Black or African American